As­traZeneca's res­pi­ra­to­ry team ac­knowl­edges its lat­est set­back, tri­al flops

As­traZeneca’s res­pi­ra­to­ry R&D group has an­oth­er set­back to re­port.

The phar­ma gi­ant’s part­ners at Dy­navax Tech­nolo­gies $DVAX filed a state­ment with the SEC to­day not­ing that the re­search team at As­traZeneca in­formed them that their Phase IIa tri­al of the TLR9 ag­o­nist AZD1419 had flopped.

There aren’t a lot of de­tails. Dy­navax wrote:

As­traZeneca will now re­view the full da­ta be­fore de­cid­ing on the next steps for the AZD1419 pro­gram. The da­ta will be pre­sent­ed at a fu­ture med­ical meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER